

Taha Merghoub

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3122421/publications.pdf>

Version: 2024-02-01

169
papers

37,410
citations

8749

75
h-index

4988

167
g-index

190
all docs

190
docs citations

190
times ranked

43330
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutational landscape determines sensitivity to PD-1 blockade in nonâ€“small cell lung cancer. <i>Science</i> , 2015, 348, 124-128.	6.0	6,756
2	Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 2189-2199.	13.9	3,753
3	Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. <i>Science</i> , 2016, 351, 1463-1469.	6.0	2,445
4	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 1976-1986.	13.9	1,495
5	Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. <i>Cell</i> , 2015, 162, 974-986.	13.5	1,408
6	Molecular Determinants of Response to Antiâ€“Programmed Cell Death (PD)-1 and Antiâ€“Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Nonâ€“Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. <i>Journal of Clinical Oncology</i> , 2018, 36, 633-641.	0.8	1,109
7	Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. <i>Nature</i> , 2017, 551, 512-516.	13.7	854
8	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Cancer Cell</i> , 2018, 33, 843-852.e4.	7.7	827
9	Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. <i>Journal of Experimental Medicine</i> , 2010, 207, 637-650.	4.2	715
10	Overcoming resistance to checkpoint blockade therapy by targeting PI3KÎ³ in myeloid cells. <i>Nature</i> , 2016, 539, 443-447.	13.7	661
11	Chromatin states define tumour-specific T cell dysfunction and reprogramming. <i>Nature</i> , 2017, 545, 452-456.	13.7	643
12	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
13	Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy. <i>Science Translational Medicine</i> , 2014, 6, 226ra32.	5.8	590
14	A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy. <i>Nature</i> , 2017, 551, 517-520.	13.7	532
15	Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 583-589.	0.6	510
16	Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas. <i>Cancer Cell</i> , 2012, 22, 668-682.	7.7	469
17	Role of the proto-oncogene <i>Pokemon</i> in cellular transformation and ARF repression. <i>Nature</i> , 2005, 433, 278-285.	13.7	461
18	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies. <i>Cancer Cell</i> , 2018, 33, 581-598.	7.7	393

#	ARTICLE	IF	CITATIONS
19	Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. <i>Cell Reports</i> , 2015, 13, 412-424.	2.9	387
20	Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. <i>Cell</i> , 2017, 170, 927-938.e20.	13.5	368
21	Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. <i>Nature Reviews Clinical Oncology</i> , 2022, 19, 37-50.	12.5	350
22	CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. <i>Nature Immunology</i> , 2020, 21, 298-308.	7.0	326
23	Monocytic CCR2+ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T-cell Infiltration into the Tumor Microenvironment. <i>Cancer Research</i> , 2012, 72, 876-886.	0.4	313
24	Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction. <i>Cell</i> , 2020, 183, 818-834.e13.	13.5	287
25	<i>PTEN</i> Loss-of-Function Alterations Are Associated With Intrinsic Resistance to BRAF Inhibitors in Metastatic Melanoma. <i>JCO Precision Oncology</i> , 2017, 1, 1-15.	1.5	275
26	Loss of NF1 in Cutaneous Melanoma Is Associated with RAS Activation and MEK Dependence. <i>Cancer Research</i> , 2014, 74, 2340-2350.	0.4	266
27	Uptake of oxidized lipids by the scavenger receptor CD36 promotes lipid peroxidation and dysfunction in CD8+ T cells in tumors. <i>Immunity</i> , 2021, 54, 1561-1577.e7.	6.6	260
28	Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: An exploratory multi-omic analysis. <i>PLoS Medicine</i> , 2017, 14, e1002309.	3.9	256
29	Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP Proteins. <i>Cancer Discovery</i> , 2018, 8, 1006-1025.	7.7	248
30	Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. <i>Nature</i> , 2021, 596, 126-132.	13.7	234
31	ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity. <i>Nature</i> , 2020, 579, 130-135.	13.7	229
32	Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation. <i>PLoS ONE</i> , 2010, 5, e10436.	1.1	222
33	Progression of RAS-Mutant Leukemia during RAF Inhibitor Treatment. <i>New England Journal of Medicine</i> , 2012, 367, 2316-2321.	13.9	222
34	PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance. <i>Nature Immunology</i> , 2019, 20, 1231-1243.	7.0	217
35	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	13.5	206
36	Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. <i>Nature Communications</i> , 2020, 11, 4011.	5.8	198

#	ARTICLE	IF	CITATIONS
37	Agonist Anti-GITR Antibody Enhances Vaccine-Induced CD8+ T-Cell Responses and Tumor Immunity. <i>Cancer Research</i> , 2006, 66, 4904-4912.	0.4	195
38	OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. <i>Journal of Experimental Medicine</i> , 2009, 206, 1103-1116.	4.2	195
39	Alternative transcription initiation leads to expression of a novel ALK isoform in cancer. <i>Nature</i> , 2015, 526, 453-457.	13.7	191
40	Regulation of B Versus T Lymphoid Lineage Fate Decision by the Proto-Oncogene LRF. <i>Science</i> , 2007, 316, 860-866.	6.0	190
41	CTLA-4 blockade drives loss of Treg stability in glycolysis-low tumours. <i>Nature</i> , 2021, 591, 652-658.	13.7	187
42	Rational design of anti-GITR-based combination immunotherapy. <i>Nature Medicine</i> , 2019, 25, 759-766.	15.2	180
43	Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF. <i>Oncogene</i> , 2012, 31, 446-457.	2.6	179
44	BCL-6 regulates chemokine gene transcription in macrophages. <i>Nature Immunology</i> , 2000, 1, 214-220.	7.0	164
45	Plzf Mediates Transcriptional Repression of HoxD Gene Expression through Chromatin Remodeling. <i>Developmental Cell</i> , 2002, 3, 499-510.	3.1	160
46	Broad-Spectrum Therapeutic Suppression of Metastatic Melanoma through Nuclear Hormone Receptor Activation. <i>Cell</i> , 2014, 156, 986-1001.	13.5	149
47	Modified Vaccinia Virus Ankara Triggers Type I IFN Production in Murine Conventional Dendritic Cells via a cGAS/STING-Mediated Cytosolic DNA-Sensing Pathway. <i>PLoS Pathogens</i> , 2014, 10, e1003989.	2.1	148
48	In-depth tissue profiling using multiplexed immunohistochemical consecutive staining on single slide. <i>Science Immunology</i> , 2016, 1, aaf6925.	5.6	142
49	Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis. <i>Cancer Discovery</i> , 2021, 11, 1212-1227.	7.7	139
50	GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability. <i>Cancer Immunology Research</i> , 2013, 1, 320-331.	1.6	135
51	Kinase Regulation of Human MHC Class I Molecule Expression on Cancer Cells. <i>Cancer Immunology Research</i> , 2016, 4, 936-947.	1.6	132
52	Pharmacologic modulation of RNA splicing enhances anti-tumor immunity. <i>Cell</i> , 2021, 184, 4032-4047.e31.	13.5	131
53	Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. <i>Journal of Experimental Medicine</i> , 2012, 209, 2113-2126.	4.2	130
54	Somatic Mutations and Neopeptide Homology in Melanomas Treated with CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 84-91.	1.6	126

#	ARTICLE	IF	CITATIONS
55	Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling. <i>Molecular Cell</i> , 2015, 59, 345-358.	4.5	125
56	Maternally transmitted severe glucose 6-phosphate dehydrogenase deficiency is an embryonic lethal. <i>EMBO Journal</i> , 2002, 21, 4229-4239.	3.5	123
57	Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. <i>Journal of the National Cancer Institute</i> , 2018, 110, 787-790.	3.0	123
58	Neutrophil phenotypes and functions in cancer: A consensus statement. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	119
59	Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. <i>EBioMedicine</i> , 2016, 6, 50-58.	2.7	113
60	Cancer-Germline Antigen Expression Discriminates Clinical Outcome to CTLA-4 Blockade. <i>Cell</i> , 2018, 173, 624-633.e8.	13.5	113
61	Non-conventional Inhibitory CD4 ⁺ Foxp3 ⁺ PD-1 ^{hi} T Cells as a Biomarker of Immune Checkpoint Blockade Activity. <i>Cancer Cell</i> , 2018, 33, 1017-1032.e7.	7.7	112
62	PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. <i>Journal of Clinical Investigation</i> , 2018, 128, 1413-1428.	3.9	111
63	Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. <i>Nature Communications</i> , 2017, 8, 14340.	5.8	110
64	Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor Growth. <i>Cell Metabolism</i> , 2017, 25, 358-373.	7.2	109
65	Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. <i>Molecular Therapy</i> , 2018, 26, 1008-1019.	3.7	103
66	Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. <i>Cancer Immunology Research</i> , 2018, 6, 189-200.	1.6	102
67	Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. <i>Science Immunology</i> , 2017, 2, .	5.6	101
68	Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor. <i>Cancer Immunology Research</i> , 2014, 2, 70-79.	1.6	100
69	Blockade of surface-bound TGF- β 2 on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. <i>Science Signaling</i> , 2017, 10, .	1.6	100
70	In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. <i>Oncogene</i> , 1999, 18, 5278-5292.	2.6	99
71	Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. <i>Blood</i> , 2010, 115, 4384-4392.	0.6	98
72	LRF Is an Essential Downstream Target of GATA1 in Erythroid Development and Regulates BIM-Dependent Apoptosis. <i>Developmental Cell</i> , 2009, 17, 527-540.	3.1	97

#	ARTICLE	IF	CITATIONS
73	Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity. <i>Cancer Cell</i> , 2021, 39, 973-988.e9.	7.7	93
74	Self-antigen-specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response. <i>Journal of Experimental Medicine</i> , 2009, 206, 849-866.	4.2	92
75	Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1327-1337.	3.2	90
76	Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. <i>Journal of Clinical Investigation</i> , 2006, 116, 1382-1390.	3.9	80
77	Neoantigen quality predicts immunoediting in survivors of pancreatic cancer. <i>Nature</i> , 2022, 606, 389-395.	13.7	80
78	Systemic Antitumor Immunity by PD-1/PD-L1 Inhibition Is Potentiated by Vascular-Targeted Photodynamic Therapy of Primary Tumors. <i>Clinical Cancer Research</i> , 2018, 24, 592-599.	3.2	75
79	Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLC. <i>Clinical Cancer Research</i> , 2020, 26, 2849-2858.	3.2	74
80	Efficacy of Intermittent Combined RAF and MEK Inhibition in a Patient with Concurrent BRAF- and NRAS-Mutant Malignancies. <i>Cancer Discovery</i> , 2014, 4, 538-545.	7.7	73
81	Altered myelopoiesis and the development of acute myeloid leukemia in transgenic mice overexpressing cyclin A1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 6853-6858.	3.3	71
82	Mutations of the PML tumor suppressor gene in acute promyelocytic leukemia. <i>Blood</i> , 2004, 103, 2358-2362.	0.6	64
83	The importance of animal models in tumor immunity and immunotherapy. <i>Current Opinion in Genetics and Development</i> , 2014, 24, 46-51.	1.5	62
84	The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease. <i>Journal of Clinical Investigation</i> , 2010, 120, 343-356.	3.9	62
85	Escape from nonsense-mediated decay associates with anti-tumor immunogenicity. <i>Nature Communications</i> , 2020, 11, 3800.	5.8	61
86	Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies. <i>Oncotarget</i> , 2016, 7, 85430-85436.	0.8	60
87	Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity. <i>PLoS ONE</i> , 2010, 5, e12670.	1.1	57
88	A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases. <i>Oncologist</i> , 2015, 20, 789-797.	1.9	57
89	Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy. <i>Onc Immunology</i> , 2016, 5, e1151595.	2.1	57
90	T cells translate individual, quantal activation into collective, analog cytokine responses via time-integrated feedbacks. <i>ELife</i> , 2014, 3, e01944.	2.8	57

#	ARTICLE	IF	CITATIONS
91	LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	54
92	Disruption of PLZF in Mice Leads to Increased T-Lymphocyte Proliferation, Cytokine Production, and Altered Hematopoietic Stem Cell Homeostasis. <i>Molecular and Cellular Biology</i> , 2004, 24, 10456-10469.	1.1	53
93	Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. <i>Cell Reports</i> , 2019, 27, 806-819.e5.	2.9	51
94	Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2200-2208.	3.2	51
95	Vaccinia Virus Subverts a Mitochondrial Antiviral Signaling Protein-Dependent Innate Immune Response in Keratinocytes through Its Double-Stranded RNA Binding Protein, E3. <i>Journal of Virology</i> , 2008, 82, 10735-10746.	1.5	49
96	Using LIBS to diagnose melanoma in biomedical fluids deposited on solid substrates: Limits of direct spectral analysis and capability of machine learning. <i>Spectrochimica Acta, Part B: Atomic Spectroscopy</i> , 2018, 146, 106-114.	1.5	48
97	Anatomic position determines oncogenic specificity in melanoma. <i>Nature</i> , 2022, 604, 354-361.	13.7	44
98	The New Era of Cancer Immunotherapy. <i>Advances in Cancer Research</i> , 2015, 128, 1-68.	1.9	41
99	Targeted APC Activation in Cancer Immunotherapy to Enhance the Abscopal Effect. <i>Frontiers in Immunology</i> , 2019, 10, 604.	2.2	40
100	Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes with PD-1 Blockade in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5131-5140.	3.2	40
101	EWS-FLI-1-Targeted Cytotoxic T-cell Killing of Multiple Tumor Types Belonging to the Ewing Sarcoma Family of Tumors. <i>Clinical Cancer Research</i> , 2012, 18, 5341-5351.	3.2	39
102	Clonal Abundance of Tumor-Specific CD4 + T Cells Potentiates Efficacy and Alters Susceptibility to Exhaustion. <i>Immunity</i> , 2016, 44, 179-193.	6.6	39
103	Myxoma Virus Induces Type I Interferon Production in Murine Plasmacytoid Dendritic Cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-Dependent Pathway. <i>Journal of Virology</i> , 2011, 85, 10814-10825.	1.5	37
104	Combination of Alphavirus Replicon Particle-Based Vaccination with Immunomodulatory Antibodies: Therapeutic Activity in the B16 Melanoma Mouse Model and Immune Correlates. <i>Cancer Immunology Research</i> , 2014, 2, 448-458.	1.6	37
105	Neoantigen-specific CD8 T cell responses in the peripheral blood following PD-L1 blockade might predict therapy outcome in metastatic urothelial carcinoma. <i>Nature Communications</i> , 2022, 13, 1935.	5.8	37
106	In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors. <i>Journal of Clinical Investigation</i> , 2019, 129, 3435-3447.	3.9	33
107	Innate Immune Response of Human Plasmacytoid Dendritic Cells to Poxvirus Infection Is Subverted by Vaccinia E3 via Its Z-DNA/RNA Binding Domain. <i>PLoS ONE</i> , 2012, 7, e36823.	1.1	32
108	iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. <i>Cancer Research</i> , 2020, 80, 1681-1692.	0.4	31

#	ARTICLE	IF	CITATIONS
109	Silibinin down-regulates PD-L1 expression in nasopharyngeal carcinoma by interfering with tumor cell glycolytic metabolism. <i>Archives of Biochemistry and Biophysics</i> , 2020, 690, 108479.	1.4	30
110	First-in-human phase 1 single-dose study of TRX-518, an anti-human glucocorticoid-induced tumor necrosis factor receptor (GITR) monoclonal antibody in adults with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3017-3017.	0.8	30
111	HMG-CoA synthase 1 is a synthetic lethal partner of BRAFV600E in human cancers. <i>Journal of Biological Chemistry</i> , 2017, 292, 10142-10152.	1.6	28
112	Improved Tumor Immunity Using Anti-Tyrosinase Related Protein-1 Monoclonal Antibody Combined with DNA Vaccines in Murine Melanoma. <i>Cancer Research</i> , 2008, 68, 9884-9891.	0.4	27
113	Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. <i>Oncotarget</i> , 2018, 9, 28702-28716.	0.8	27
114	IL-6/NOS2 inflammatory signals regulate MMP-9 and MMP-2 activity and disease outcome in nasopharyngeal carcinoma patients. <i>Tumor Biology</i> , 2016, 37, 3505-3514.	0.8	24
115	Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice. <i>Blood</i> , 2014, 123, 2172-2180.	0.6	23
116	Phenformin Enhances the Efficacy of ERK Inhibition in NF1-Mutant Melanoma. <i>Journal of Investigative Dermatology</i> , 2017, 137, 1135-1143.	0.3	23
117	Strategies for Predicting Response to Checkpoint Inhibitors. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 383-395.	1.2	23
118	Fundamental immune oncogenicity trade-offs define driver mutation fitness. <i>Nature</i> , 2022, 606, 172-179.	13.7	23
119	Antiangiogenic therapy and immune checkpoint blockade go hand in hand. <i>Annals of Translational Medicine</i> , 2017, 5, 497-497.	0.7	21
120	Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. <i>Cell Reports</i> , 2021, 34, 108620.	2.9	21
121	mTORC1/autophagy-regulated MerTK in mutant BRAFV600 melanoma with acquired resistance to BRAF inhibition. <i>Oncotarget</i> , 2017, 8, 69204-69218.	0.8	21
122	Potentiating vascular-targeted photodynamic therapy through CSF-1R modulation of myeloid cells in a preclinical model of prostate cancer. <i>Oncolmunology</i> , 2019, 8, e1581528.	2.1	20
123	The metabolic/pH sensor soluble adenylyl cyclase is a tumor suppressor protein. <i>Oncotarget</i> , 2016, 7, 45597-45607.	0.8	19
124	Leveraging Systematic Functional Analysis to Benchmark an <i>In Silico</i> Framework Distinguishes Driver from Passenger MEK Mutants in Cancer. <i>Cancer Research</i> , 2020, 80, 4233-4243.	0.4	18
125	Mechanisms of Immunization Against Cancer Using Chimeric Antigens. <i>Molecular Therapy</i> , 2008, 16, 773-781.	3.7	17
126	Toxicological and pharmacological assessment of AGEN1884, a novel human IgG1 anti-CTLA-4 antibody. <i>PLoS ONE</i> , 2018, 13, e0191926.	1.1	17

#	ARTICLE	IF	CITATIONS
127	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/â~ trastuzumab in patients with breast cancer brain metastases. <i>Npj Breast Cancer</i> , 2022, 8, 50.	2.3	17
128	Immune Rejection of Mouse Tumors Expressing Mutated Self. <i>Cancer Research</i> , 2009, 69, 3545-3553.	0.4	15
129	Phase IB Study of G1TR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 3990-4002.	3.2	15
130	NSCLC, early stage Neoadjuvant anti-PD1, nivolumab, in early stage resectable non-small-cell lung cancer. <i>Annals of Oncology</i> , 2016, 27, vi576.	0.6	14
131	Modeling Acute Promyelocytic Leukemia in the Mouse: New Insights in the Pathogenesis of Human Leukemias. <i>Blood Cells, Molecules, and Diseases</i> , 2001, 27, 231-248.	0.6	12
132	Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. <i>Vaccine</i> , 2011, 29, 3646-3654.	1.7	12
133	Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope. <i>PLoS ONE</i> , 2011, 6, e21214.	1.1	12
134	The Dietary Supplement Chondroitin-4-Sulfate Exhibits Oncogene-Specific Pro-tumor Effects on BRAF V600E Melanoma Cells. <i>Molecular Cell</i> , 2018, 69, 923-937.e8.	4.5	12
135	Polyphenols from <i>Pennisetum glaucum</i> grains induce MAP kinase phosphorylation and cell cycle arrest in human osteosarcoma cells. <i>Journal of Functional Foods</i> , 2019, 54, 422-432.	1.6	12
136	Massively parallel sequencing analysis of benign melanocytic naevi. <i>Histopathology</i> , 2019, 75, 29-38.	1.6	12
137	The T Cell Cytolytic Molecules Fas Ligand and TRAIL, the Trafficking Molecules CCR9, Î²7 Integrin and PSGL-1, and the Immune Modulating Molecules OX40, CEACAM1, and CTLA4 Are Required for Thymic Graft-Versus-Host Disease. <i>Blood</i> , 2008, 112, 65-65.	0.6	12
138	Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma. <i>Cancers</i> , 2022, 14, 2638.	1.7	12
139	Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent. <i>PLoS ONE</i> , 2013, 8, e82496.	1.1	11
140	Four-month course of adjuvant dabrafenib in patients with surgically resected stage IIIc melanoma characterized by a BRAFV600E/K mutation. <i>Oncotarget</i> , 2017, 8, 105000-105010.	0.8	10
141	Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	10
142	Elucidating mechanisms of antitumor immunity mediated by live oncolytic vaccinia and heat-inactivated vaccinia. , 2021, 9, e002569.		9
143	The immunological impact of the RAF inhibitor BMS908662: Preclinical and early clinical experience in combination with CTLA-4 blockade.. <i>Journal of Clinical Oncology</i> , 2012, 30, 2521-2521.	0.8	9
144	Protein Expression Analysis of Melanocyte Differentiation Antigen TRP-2. <i>American Journal of Dermatopathology</i> , 2016, 38, 201-207.	0.3	8

#	ARTICLE	IF	CITATIONS
145	Tumor-induced double positive T cells display distinct lineage commitment mechanisms and functions. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	8
146	Genetics and immunology: reinvigorated. <i>Oncolmmunology</i> , 2015, 4, e1029705.	2.1	7
147	Development of effective vaccines for old mice in a tumor model. <i>Vaccine</i> , 2009, 27, 1093-1100.	1.7	6
148	Myeloid-derived suppressor cells and the efficacy of CD8+T-cell immunotherapy. <i>Oncolmmunology</i> , 2013, 2, e22764.	2.1	6
149	Isoform specific anti-TGF β 2 therapy enhances antitumor efficacy in mouse models of cancer. <i>Communications Biology</i> , 2021, 4, 1296.	2.0	6
150	Atypical t(15;17)(q13;q12) in a patient with all-trans retinoic acid refractory secondary acute promyelocytic leukemia:. <i>Cancer Genetics and Cytogenetics</i> , 2002, 138, 143-148.	1.0	5
151	Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. <i>Immunotherapy</i> , 2015, 7, 981-997.	1.0	5
152	One checkpoint may hide another: inhibiting the TGF β 2 signaling pathway enhances immune checkpoint blockade. <i>Hepatobiliary Surgery and Nutrition</i> , 2019, 8, 289-294.	0.7	5
153	Innate immune checkpoints for cancer immunotherapy: expanding the scope of non T cell targets. <i>Annals of Translational Medicine</i> , 2020, 8, 1031-1031.	0.7	5
154	In vitro assays for effector T cell functions and activity of immunomodulatory antibodies. <i>Methods in Enzymology</i> , 2020, 631, 43-59.	0.4	5
155	Therapeutic antibody activation of the glucocorticoid-induced TNF receptor by a clustering mechanism. <i>Science Advances</i> , 2022, 8, eabm4552.	4.7	5
156	Curbing Tregs™ (Lack of) Enthusiasm. <i>Cell</i> , 2017, 169, 981-982.	13.5	4
157	Abstract 3643: INCAGN1876, a unique GITR agonist antibody that facilitates GITR oligomerization. , 2017, , .		2
158	Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness. <i>JCI Insight</i> , 2021, 6, .	2.3	2
159	Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody.. <i>Blood</i> , 2007, 110, 1788-1788.	0.6	2
160	Immunotherapy and the belly of the beast. <i>Journal of Experimental Medicine</i> , 2014, 211, 2327-2328.	4.2	1
161	POKEMON Is a Proto-Oncogene Which Plays a Key Role in Lymphomagenesis.. <i>Blood</i> , 2004, 104, 3489-3489.	0.6	1
162	T Cell Immunotherapies Trigger Neutrophil Activation to Eliminate Tumor Antigen Escape Variants. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1

#	ARTICLE	IF	CITATIONS
163	Plasma secretome analyses identify IL-8 and nitrites as predictors of poor prognosis in nasopharyngeal carcinoma patients. <i>Cytokine</i> , 2022, 153, 155852.	1.4	1
164	LRP/Pokemon Plays a Pivotal Role in B Versus T Lymphoid Lineage Fate Decision at the Early Lymphoid Progenitor Stage by Opposing Notch1 Signaling. <i>Blood</i> , 2006, 108, 778-778.	0.6	0
165	Monocytic CCR2+ Myeloid Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD8 T Cell Infiltration Into the Tumor Microenvironment. <i>Blood</i> , 2011, 118, 2171-2171.	0.6	0
166	Interfering with Helios-induced regulatory T cell stability as a strategy for cancer immunotherapy. <i>Translational Cancer Research</i> , 2016, 5, S1116-S1118.	0.4	0
167	Chromatin State Dynamics Underlying CD8 T Cell Differentiation and Dysfunction in Cancer. <i>Blood</i> , 2016, 128, 861-861.	0.6	0
168	Pre-Existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
169	Pulsatile MEK Inhibition Improves Anti-Tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0